Baylosis, Elaiza M.
HRN: 25-25-46 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/12/2024
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
06/12/2024
06/18/2024
IV
300mg
Q12h
PTB (clinical); Pneumonia
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes